Detailed data of the 12 trials included in the meta-analysis.

Note: 3134 patients were included in the meta-analysis, with 1570 assigned to the experimental groups (Exp) treated with immunotherapy and 1564 in the control groups (Con).Abbreviations: CR, complete response rate; OS, overall survival; PFS, progression-free survival; PR, partial response rate; TER, total effective rate, which is equal to CR plus PR; No, no detailed data; BSC, best supportive care without drug regimen; C, cisplatin; CE: cisplatin + etoposide.; CHT, chemotherapy (docetaxel + cisplatin); CHIMT, CHT + an immunomodulatory adjuvant system; CIK, cytokine-induced killer biotherapy; D, docetaxel; EGF, epidermal growth factor; GC: gemcitabine-cisplatin; GM-CSF, granulocyte macrophage-colony stimulating factor; L-BLP25, BLP25 liposome vaccine; MLT, melatonin; MVP, mitomycin C + vinblastine + cisplatin; NP, vinorelbine-platinum; rIL-2, recombinant interleukin 2; SRL172, killed Mycobacterium vaccae; TC, taxane + cisplatin; TCG: trastuzumab + gemcitabine-cisplatin; TP, docetaxel + cisplatin; V, vinorelbine.